2000
Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of Plasmodium chabaudi-Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial Anemia
Martiney J, Sherry B, Metz C, Espinoza M, Ferrer A, Calandra T, Broxmeyer H, Bucala R. Macrophage Migration Inhibitory Factor Release by Macrophages after Ingestion of Plasmodium chabaudi-Infected Erythrocytes: Possible Role in the Pathogenesis of Malarial Anemia. Infection And Immunity 2000, 68: 2259-2267. PMID: 10722628, PMCID: PMC97412, DOI: 10.1128/iai.68.4.2259-2267.2000.Peer-Reviewed Original ResearchMeSH KeywordsAnemiaAnimalsBone MarrowCells, CulturedDose-Response Relationship, DrugEnzyme-Linked Immunosorbent AssayErythrocytesErythroid Precursor CellsErythropoiesisErythropoietinFemaleImmunohistochemistryLeukopoiesisLiverMacrophage Migration-Inhibitory FactorsMacrophagesMalariaMiceMice, Inbred BALB CMice, Inbred C3HPlasmodium chabaudiSpleenTime FactorsConceptsMacrophage migration inhibitory factorChabaudi-infected erythrocytesMalarial anemiaP. chabaudi-infected miceBALB/c miceP. chabaudi-infected erythrocytesTumor necrosis factor alphaMacrophage migration inhibitory factor releaseHuman falciparum malariaRed blood cell destructionPlasmodium falciparum infectionMigration inhibitory factorNecrosis factor alphaSuppression of erythropoiesisAntibody neutralization studiesBlood cell destructionHost-derived factorsPlasmodium chabaudi-infected erythrocytesErythropoiesis inhibitorMalaria anemiaActive diseaseCerebral malariaChabaudi infectionFalciparum malariaFalciparum infectionImmunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo
Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y. Immunological Evidence that Non-carboxymethyllysine Advanced Glycation End-products Are Produced from Short Chain Sugars and Dicarbonyl Compounds in vivo. Molecular Medicine 2000, 6: 114-125. PMID: 10859028, PMCID: PMC1949938, DOI: 10.1007/bf03401779.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodiesCattleChromatography, AffinityCross ReactionsDiabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycation End Products, AdvancedGlyceraldehydeGlyoxalHumansImmunoblottingKidney Failure, ChronicLysineMaillard ReactionOxidation-ReductionPyruvaldehydeRabbitsRenal DialysisConceptsAGE antibodyCML-AGEDiabetic patientsAGE-bovine serum albuminShort Chain SugarsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsAutoxidation of sugarsImmunization of rabbitsCML-BSADiabetic serumSerum albuminAdvanced glycationAGE contentSugar autoxidationRabbit serum albuminAGE modificationAntibodiesImmunological evidenceApparent molecular weightPatientsAge 3AgeImmunoblot analysis
1999
Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †
Al-Abed Y, Bucala R. Structure of a Synthetic Glucose Derived Advanced Glycation End Product That Is Immunologically Cross-Reactive with Its Naturally Occurring Counterparts †. Bioconjugate Chemistry 1999, 11: 39-45. PMID: 10639083, DOI: 10.1021/bc990061q.Peer-Reviewed Original ResearchConceptsAdvanced glycation end productsAnti-AGE antibodyGlycation end productsLow-density lipoproteinAGE-modified formCertain diabetic complicationsClasses of antibodiesBeta-amyloid peptideDiabetic complicationsPathological sequelaePrognostic informationAGE formationAGE adductsImmunoreactive fractionEnd productsInhibition of formationVivo ageAgeAntibodiesLines of evidenceVivoCross-linking adductsGlucoseTissueComplications
1998
Local Regulation of Macrophage Subsets in the Adult Rat Testis: Examination of the Roles of the Seminiferous Tubules, Testosterone, and Macrophage-Migration Inhibitory Factor1
Meinhardt A, Bacher M, Metz C, Bucala R, Wreford N, Lan H, Atkins R, Hedger M. Local Regulation of Macrophage Subsets in the Adult Rat Testis: Examination of the Roles of the Seminiferous Tubules, Testosterone, and Macrophage-Migration Inhibitory Factor1. Biology Of Reproduction 1998, 59: 371-378. PMID: 9687310, DOI: 10.1095/biolreprod59.2.371.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorSeminiferous tubule functionLeydig cell functionAdult rat testisMacrophage subsetsMacrophage numbersT implantsTubule functionAbdominal testesRat testisLeydig cellsResident macrophagesCytokine macrophage migration inhibitory factorMonocyte/macrophage subsetsCell functionMacrophage surface antigensResident macrophage numbersMacrophage migration inhibitoryMonoclonal antibody ED2MIF levelsLack of expressionSurface antigenInhibitory factorTestosterone implantsScrotal testesInvolvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis
Leech M, Metz C, Santos L, Peng T, Holdsworth S, Bucala R, Morand E. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis & Rheumatism 1998, 41: 910-917. PMID: 9588744, DOI: 10.1002/1529-0131(199805)41:5<910::aid-art19>3.0.co;2-e.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalArthritis, ExperimentalBlotting, WesternCell CountCells, CulturedDose-Response Relationship, DrugEdemaEnzyme-Linked Immunosorbent AssayImmunohistochemistryMacrophage Migration-Inhibitory FactorsMacrophagesMaleNeutralization TestsRatsRats, Sprague-DawleySynovial MembraneConceptsMacrophage migration inhibitory factorRat adjuvant arthritisAdjuvant arthritisMigration inhibitory factorSynovial macrophagesRat synoviumLevels of MIFRole of MIFInhibitory factorMonoclonal antibodiesArthritis clinical scoresT cell accumulationDose-dependent inhibitionEnzyme-linked immunosorbentMIF treatmentAdjuvant injectionMAb treatmentClinical scoresED-1Leukocyte numbersSpecific monoclonal antibodiesClinical aspectsT cellsArthritisMacrophage activation
1997
Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs
Stitt A, He C, Friedman S, Scher L, Rossi P, Ong L, Founds H, Li Y, Bucala R, Vlassara H. Elevated AGE-Modified ApoB in Sera of Euglycemic, Normolipidemic Patients with Atherosclerosis: Relationship to Tissue AGEs. Molecular Medicine 1997, 3: 617-627. PMID: 9323713, PMCID: PMC2230092, DOI: 10.1007/bf03401819.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAgingApolipoproteins BArteriosclerosisCarotid ArteriesCollagenEndothelium, VascularEnzyme-Linked Immunosorbent AssayFemaleGlycation End Products, AdvancedHumansImmunohistochemistryMacrophagesMaleMicroscopy, FluorescenceMiddle AgedReceptor for Advanced Glycation End ProductsReceptors, ImmunologicRegression AnalysisConceptsSmooth muscle cellsAGE-specific receptorsMononuclear cellsAtherosclerotic vascular diseaseOcclusive atherosclerotic diseaseDevelopment of hyperlipidemiaLipid-laden macrophagesYoung healthy personsEarly-stage lesionsCardiac bypass patientsAGE-R1Nondiabetic patientsAsymptomatic patientsAsymptomatic personsBypass patientsNormolipidemic patientsAtherosclerotic diseaseDistribution of ageVascular diseaseInflammatory responseLate-stage plaquesAtheromatous lesionsEarly lesionsFatty streaksNondiabetic etiology
1995
MIF as a glucocorticoid-induced modulator of cytokine production
Calandra T, Bernhagen J, Metz C, Spiegel L, Bacher M, Donnelly T, Cerami A, Bucala R. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995, 377: 68-71. PMID: 7659164, DOI: 10.1038/377068a0.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBlotting, WesternCell LineCytokinesDexamethasoneEnzyme-Linked Immunosorbent AssayFemaleGlucocorticoidsHumansHydrocortisoneImmunityInflammationLipopolysaccharidesMacrophage ActivationMacrophage Migration-Inhibitory FactorsMacrophagesMiceMice, Inbred BALB CRatsRats, Sprague-DawleyRecombinant ProteinsShock, SepticT-LymphocytesConceptsMacrophage migration inhibitory factorCounter-regulatory systemsMigration inhibitory factorProtein macrophage migration inhibitory factorGlucocorticoid protectionLethal endotoxaemiaMIF productionCytokine productionCytokine secretionMacrophage cytokinesEndogenous mediatorsImmunosuppressive propertiesImmune responseGlucocorticoid hormonesInhibitory factorHormonal systemsCritical mediatorUnexpected findingMediatorsVital functionsEndotoxaemiaCytokinesGlucocorticoidsMonocytesPituitaryFormation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes
Beisswenger P, Makita Z, Curphey T, Moore L, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H. Formation of Immunochemical Advanced Glycosylation End Products Precedes and Correlates With Early Manifestations of Renal and Retinal Disease in Diabetes. Diabetes 1995, 44: 824-829. PMID: 7789650, DOI: 10.2337/diab.44.7.824.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation end productsEnzyme-linked immunosorbent assayAlbumin excretionDuration of diabetesElevated levelsNormal renal statusTissue advanced glycosylation end productsDiabetic vascular complicationsTissue AGE levelsGlycosylation end productsEvident retinopathyMicroalbuminuric phaseOvert microangiopathySevere retinopathyVascular complicationsDiabetic nephropathyRenal statusUrinary albuminProliferative retinopathyEarly retinopathyHigher age levelsSignificant elevationRetinopathyRetinal diseasesEarly manifestation
1992
Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation
Makita Z, Vlassara H, Rayfield E, Cartwright K, Friedman E, Rodby R, Cerami A, Bucala R. Hemoglobin-AGE: A Circulating Marker of Advanced Glycosylation. Science 1992, 258: 651-653. PMID: 1411574, DOI: 10.1126/science.1411574.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgingBiomarkersDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Enzyme-Linked Immunosorbent AssayGlycosylationGuanidinesHemoglobinsHumansMiddle AgedConceptsAdvanced glycosylation end productsAdvanced glycosylationAGE-modified formAGE-specific antibodiesComplications of agingDiabetes-induced hyperglycemiaAge-related complicationsGlycosylation end productsCirculating MarkersDiabetic patientsRenal diseaseGlucose-derived Amadori productsNormal individualsComplicationsPatientsTissue modificationsTissue proteinsHemoglobinAmadori productsEnd productsPercentDiabeticsHyperglycemiaAtherosclerosisDiabetes